Home / Peptides

Peptides A-Z

FDA status as of 2026-11-16, the doses a label or trial actually used, and what nobody knows yet.

2026 changed the rules. In April the FDA took a dozen peptides (including BPC-157, TB-500, KPV and MOTS-c) off its "significant safety risk" compounding list, and on October 30 HHS published a draft policy that would let pharmacies compound six of them for individual prescriptions. None of that is an FDA approval.

FDA-approved

A label sets the dose, the warnings and how to mix it.

Bremelanotide (PT-141)

Melanocortin agonist (Vyleesi) approved for low sexual desire in premenopausal women. 1.75 mg as needed.

Elamipretide (SS-31)

Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.

Orforglipron (Foundayo)

Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.

Semaglutide

Weekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).

Tesamorelin

GHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.

Tirzepatide

Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.

In clinical trials

Doses come from published trials, not a label.

Cagrilintide (CagriSema)

Long-acting amylin analogue from Novo Nordisk, paired with semaglutide as CagriSema. Not approved yet.

Retatrutide

Weekly GIP, GLP-1 and glucagon agonist from Lilly. Phase 3, not approved; up to 28% weight loss in trials.

Not FDA-approved

No approved product; most have no established human dose.

AOD-9604

Growth hormone fragment developed as an obesity pill. Failed phase 2b; development stopped in 2007.

BPC-157

15-amino-acid peptide studied mostly in animals. Not approved; no established human dose.

CJC-1295

Long-acting GHRH analogue. Not approved and not compoundable; no trial of the popular ipamorelin combo.

DSIP (delta sleep-inducing peptide)

Nine-amino-acid sleep peptide from the 1970s. Mixed IV studies; advisory committee voted against it in 2026.

Epitalon (epithalon)

Four-amino-acid peptide modeled on a pineal extract. Small, non-randomized studies only; no established dose.

GHK-Cu (copper peptide)

Copper-binding tripeptide used in skin care. Topical studies only; no human injection data.

Ipamorelin

Ghrelin-receptor agonist. Failed a phase 2 trial; not approved and not compoundable.

KLOW and GLOW blends

Seller-defined mixes of GHK-Cu, BPC-157, TB-500 (GLOW) plus KPV (KLOW). No human data for any blend.

KPV

Three-amino-acid fragment of alpha-MSH studied in animal colitis models. No human dosing data.

MOTS-c

16-amino-acid mitochondrial peptide studied in animals. Not approved; no human data for MOTS-c itself.

NAD+ injections

Coenzyme sold alongside peptides. No approved injection; one small IV pharmacokinetic study.

Selank

Tuftsin-analogue peptide used in Russia. Not FDA-approved and not compoundable in the US.

Semax

Nasal ACTH-fragment peptide used in Russia. Not FDA-approved; no FDA-reviewed dosing.

Sermorelin

The first 29 amino acids of GHRH. Former brand Geref was withdrawn in 2009; no product is marketed today.

TB-500 (thymosin beta-4)

Name used for thymosin beta-4 and for a 7-amino-acid fragment of it. Not approved; no human dose data for the fragment.

Sources

  1. FDA: 503A bulk drug substance categories (updated May 14, 2026, PDF)
  2. Federal Register (public inspection) 2026-07361: peptide category changes
  3. Manufacturing Chemist: FDA panel backs six peptides for pharmacy compounding
  4. Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)
  5. Venable LLP: HHS announces interim enforcement discretion for certain peptides (Nov 2026)

Last checked 2026-11-16. How we pick and check sources: methodology.